FDA clears a test of a brain-fluid drain in early Alzheimer's, maker says

CereVasc, a Boston medical device company, said on October 29, 2026 that the US Food and Drug Administration (FDA) has approved a study of its eShunt System in people with early symptomatic Alzheimer’s disease, meaning people who already show early signs of the illness.¹ The eShunt is a small implant designed to drain some of the clear fluid that bathes the brain and spinal cord into the body’s veins.¹ The company plans to test whether this extra fluid turnover might help the brain clear away harmful substances linked to Alzheimer’s.¹

What the FDA granted is called an investigational device exemption, or IDE: permission to use a device that is not yet approved in a formal study. It is not a judgment that the device helps. The company’s own release states that the eShunt is investigational, has not been approved by the FDA or any other regulator for sale, and that its safety and effectiveness “have not yet been established.”¹

What the device is and how it is placed

The eShunt is described as a minimally invasive, endovascular shunt. Endovascular means it is put in place from inside a blood vessel rather than by opening the skull.¹ The company says it reaches the brain through a vein and then crosses the tough outer lining of the brain to sit where it can drain cerebrospinal fluid, the clear liquid around the brain and spine.¹ Trade coverage has described the implant as including a self-expanding anchor made of nitinol, a flexible metal alloy.²

The device was first built for a different problem. Its main target is communicating hydrocephalus, a condition where too much of this fluid builds up in the brain.¹ The usual treatment today is brain surgery to place a conventional shunt, a tube that runs from the brain to the belly, known as a VP shunt.³ CereVasc has said its approach is meant to avoid invasive surgery, general anesthesia, long hospital stays and pain management after the procedure, though these are the company’s stated aims rather than measured results.⁴ The idea for the device came from two neurosurgeons at Tufts Medical Center, Carl Heilman and Adel Malek, according to the company.⁵

Why drain brain fluid in Alzheimer’s?

Alzheimer’s is the most common cause of dementia. The company’s release cites an estimated 7.4 million Americans aged 65 and older living with it, a number projected to reach 13.8 million by 2060.¹ CereVasc’s reasoning is that the brain has a natural process for clearing waste, and that moving fluid through it faster might support that process.¹

The company’s announcement quoted Dr. Adnan Siddiqui, Vice Chairman of Neurosurgery at SUNY Buffalo’s Jacobs School of Medicine and CEO of the Jacobs Institute:¹

“Investigating mechanisms to improve the brain’s clearance pathways can potentially make a big difference in disease progression and is exactly the kind of approach we need to investigate.”

He also linked the timing to an FDA effort he called the Neuroscience Advancement and Innovation Nexus, which he said has Alzheimer’s prevention and early intervention as its first focus.¹ The release does not say what role, if any, Siddiqui has in the planned study.

An old idea with a mixed past

Draining brain fluid to treat dementia is not new. According to a 2002 summary from the American Academy of Neurology, shunting for dementia was first described in 1969 and was largely abandoned because of mixed results and too many side effects from the shunts.⁶

In 2002, researchers from Stanford University, the University of Washington and the Barrow Neurological Institute published a small trial in the journal Neurology testing a surgically implanted, low-flow shunt in people with Alzheimer’s.⁶ Twelve people completed testing with the shunt and 11 served as a comparison group.⁶ Over 12 months, the shunted group stayed relatively stable on memory and thinking tests while the comparison group declined.⁶ The researchers said the group was too small to make broad claims about safety, and that more definitive testing was needed.⁶ That study was funded by a company, Eunroe Inc., and a Stanford research fund.⁶ A larger trial was underway at the time, but the sources available here do not report its outcome.⁶ That earlier work used a different device placed by open surgery, so its results cannot be carried over to the eShunt.

What this news does not show

• No Alzheimer’s results. The announcement is about permission to study the device. No data on people with Alzheimer’s using the eShunt were reported.¹
• No study details. The release does not say how many people will take part, where, for how long, what will be measured, or whether there will be a comparison group.¹
• Not yet proven even for its main use. The eShunt has not been approved for hydrocephalus either; that large trial is still running.³
• The main trial left Alzheimer’s out. The large hydrocephalus trial excluded people with an established diagnosis of Alzheimer’s, Parkinson’s or Lewy body dementia, so it will not directly answer the Alzheimer’s question.⁷

The device’s track record so far

Most of the eShunt’s testing has been in normal pressure hydrocephalus (NPH), a fluid buildup in older adults that causes trouble walking, thinking problems and loss of bladder control.³ Estimates of how common it is differ between CereVasc’s own releases: earlier statements cited more than 700,000 Americans, while the June 2026 release cited about 800,000 people in the US.⁴³

The FDA first cleared a small pilot study of the eShunt in NPH in early 2022.⁴ A separate study in Argentina treated its first NPH patient in April 2022.⁵ In August 2024, the FDA gave the device “breakthrough device” status for NPH, a program that offers priority review and more contact with the agency; the company said pilot study data supported that decision.² Breakthrough status speeds up review but is not an approval.

The larger test, called STRIDE, compares the eShunt head to head with the standard VP shunt in older adults with NPH.³ Patients are assigned by chance to one or the other, and the people scoring outcomes do not know which treatment each patient got.⁷ The company said in June 2026 that enrollment was complete at 32 sites in the United States, Canada and Argentina.³ The trial registry lists an estimated 230 participants, main safety and effectiveness checks at 6 months, and a primary completion date of January 2027.⁸ CereVasc has said the results are meant to support an application for FDA approval in NPH.³

Who is behind it

CereVasc is a privately held, venture-funded company based in Massachusetts.⁵ Trade coverage in 2024 reported it had completed the initial closing of a $70 million funding round.² The latest announcement quotes Tony Kingsley as President and Chief Executive Officer, who said the company hopes to “build on our clinical experience with the eShunt System” and work with Alzheimer’s experts.¹ Earlier releases, including one from June 2026, named Dan Levangie as chairman and CEO.³

Everything reported here about the new Alzheimer’s study comes from the company’s own press release. No independent outlet in the sources had described the study design, and the FDA’s decision documents were not among them.

What to watch next

• A public trial registration for the Alzheimer’s study, which would show its size, design and what it measures.
• Results from the STRIDE trial in NPH, which would give the most complete picture so far of the eShunt’s safety in older adults; the registry lists primary completion in January 2027.⁸
• Whether any Alzheimer’s study compares the device against people who do not receive it, the kind of comparison that the small 2002 shunt study used.⁶

For now, the news is a regulatory green light to test an old idea with a newer, less invasive device. Whether it changes anything for people with Alzheimer’s is an open question that only the study itself can start to answer.